OAKVILLE, ON, June 9, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held on June 9, 2017, in Oakville, Ontario.
Election of Directors
The seven (7) candidates nominated for election to Concordia's Board of Directors ("Board"), and listed in the Company's Management Information Circular, dated May 8, 2017, were elected by a majority of the votes cast by shareholders present or represented by proxy at the Meeting. The voting results are as follows:
Francis Perier, Jr.
In addition, at the Meeting all resolutions put to a vote were passed, including the resolutions to approve: the re-appointment of PricewaterhouseCoopers LLP as the auditor of the Company; the Company's stock option plan; and the Company's long term incentive plan.
Concordia is a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products. The Company has an international footprint with sales in more than 90 countries, and has a diversified portfolio of more than 200 established, off-patent products. Concordia also markets Photofrin® for the treatment of certain rare forms of cancer.
Concordia operates out of facilities in Oakville, Ontario and, through its subsidiaries, operates out of facilities in Bridgetown, Barbados; London, England and Mumbai, India.
SOURCE Concordia International Corp.